{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:29:53Z","timestamp":1743013793746,"version":"3.40.3"},"publisher-location":"Cham","reference-count":75,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030143657"},{"type":"electronic","value":"9783030143664"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-030-14366-4_10","type":"book-chapter","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T09:04:03Z","timestamp":1558947843000},"page":"171-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity"],"prefix":"10.1007","author":[{"given":"Marc G.","family":"Berger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Bourgne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, Luben R, Hayat S, Wang TT, Zhao Z, Cirlan I, Pugh TJ, Soave D, Ng K, Latimer C, Hardy C, Raine K, Jones D, Hoult D, Britten A, McPherson JD, Johansson M, Mbabaali F, Eagles J, Miller JK, Pasternack D, Timms L, Krzyzanowski P, Awadalla P, Costa R, Segal E, Bratman SV, Beer P, Behjati S, Martincorena I, Wang JCY, Bowles KM, Quir\u00f3s JR, Karakatsani A, La Vecchia C, Trichopoulou A, Salamanca-Fern\u00e1ndez E, Huerta JM, Barricarte A, Travis RC, Tumino R, Masala G, Boeing H, Panico S, Kaaks R, Kr\u00e4mer A, Sieri S, Riboli E, Vineis P, Foll M, McKay J, Polidoro S, Sala N, Khaw K-T, Vermeulen R, Campbell PJ, Papaemmanuil E, Minden MD, Tanay A, Balicer RD, Wareham NJ, Gerstung M, Dick JE, Brennan P, Vassiliou GS, Shlush LI (2018) Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559:400\u2013404","journal-title":"Nature"},{"issue":"Suppl 2","key":"10_CR2","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G (2015) A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol 94(Suppl 2):S141\u2013S147","journal-title":"Ann Hematol"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2018.00194","volume":"8","author":"M Bocchia","year":"2018","unstructured":"Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sor\u00e0 F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Barat\u00e8 C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D (2018) Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission. Front Oncol 8:194","journal-title":"Front Oncol"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","volume":"3","author":"D Bonnet","year":"1997","unstructured":"Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730\u2013737","journal-title":"Nat Med"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","volume":"132","author":"S Branford","year":"2018","unstructured":"Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, Shahrin NH, Marum JE, Nataren N, Parker WT, Geoghegan J, Feng J, Shanmuganathan N, Mueller MC, Dietz C, Stangl D, Donaldson Z, Altamura H, Georgievski J, Braley J, Brown A, Hahn C, Walker I, Kim S-H, Choi S-Y, Park S-H, Kim D-W, White DL, Yong ASM, Ross DM, Scott HS, Schreiber AW, Hughes TP (2018) Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood 132:948\u2013961","journal-title":"Blood"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.stem.2014.07.005","volume":"15","author":"N Cabezas-Wallscheid","year":"2014","unstructured":"Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, Weichenhan D, Lier A, von Paleske L, Renders S, W\u00fcnsche P, Zeisberger P, Brocks D, Gu L, Herrmann C, Haas S, Essers MAG, Brors B, Eils R, Huber W, Milsom MD, Plass C, Krijgsveld J, Trumpp A (2014) Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell 15:507\u2013522","journal-title":"Cell Stem Cell"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1182\/blood.V38.6.671.671","volume":"38","author":"GP Canellos","year":"1971","unstructured":"Canellos GP, DeVita VT, Whang-Peng J, Carbone PP (1971) Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood 38:671\u2013679","journal-title":"Blood"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"J-C Chomel","year":"2011","unstructured":"Chomel J-C, Bonnet M-L, Sorel N, Bertrand A, Meunier M-C, Fichelson S, Melkus M, Bennaceur-Griscelli A, Guilhot F, Turhan AG (2011) Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118:3657\u20133660","journal-title":"Blood"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS, Bhatia R (2011) Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118:5565\u20135572","journal-title":"Blood"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G (2012) Molecular pathways: BCR-ABL. Clin Cancer Res 18:930\u2013937","journal-title":"Clin Cancer Res"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532\u20134539","journal-title":"Blood"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121:396\u2013409","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"10_CR13","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","volume":"94","author":"NCP Cross","year":"2015","unstructured":"Cross NCP, Hochhaus A, M\u00fcller MC (2015) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94(Suppl 2):S219\u2013S225","journal-title":"Ann Hematol"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640\u20132653","journal-title":"Blood"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P, Mencia-Trinchant N, Savenkov O, Simon MS, Cheang G, Lee S, Samuel M, Ritchie EK, Guzman ML, Ballman KV, Roboz GJ, Hassane DC (2018) Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med 24:1015\u20131023","journal-title":"Nat Med"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, Investigators IRIS (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566","journal-title":"Nat Med"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.leu.2403649","volume":"19","author":"W Eisterer","year":"2005","unstructured":"Eisterer W, Jiang X, Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, Auewarakul C, Barnett MJ, Eaves CJ, Eaves AC (2005) Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19:435\u2013441","journal-title":"Leukemia"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Land\u00e9n M, H\u00f6glund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Gr\u00f6nberg H, Hultman CM, McCarroll SA (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477\u20132487","journal-title":"N Engl J Med"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini A, Thongjuea S, Barkas N, Woll PS, Povinelli BJ, Booth CAG, Sopp P, Norfo R, Rodriguez-Meira A, Ashley N, Jamieson L, Vyas P, Anderson K, Segerstolpe \u00c5, Qian H, Olsson-Str\u00f6mberg U, Mustjoki S, Sandberg R, Jacobsen SEW, Mead AJ (2017) Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med 23:692\u2013702","journal-title":"Nat Med"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","volume":"344","author":"JM Goldman","year":"2001","unstructured":"Goldman JM, Melo JV (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1084\u20131086","journal-title":"N Engl J Med"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV (2003) Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 349:1451\u20131464","journal-title":"N Engl J Med"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, J\u00f8rgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319\u2013325","journal-title":"Blood"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0145-2126(79)90041-9","volume":"3","author":"MF Greaves","year":"1979","unstructured":"Greaves MF, Verbi W, Reeves BR, Hoffbrand AV, Drysdale HC, Jones L, Sacker LS, Samaratunga I (1979) \u201cPre-B\u201d phenotypes in blast crisis of Ph1 positive CML: evidence for a pluripotential stem cell \u201ctarget\u201d. Leuk Res 3:181\u2013191","journal-title":"Leuk Res"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0950-3536(87)80035-5","volume":"1","author":"J Groffen","year":"1987","unstructured":"Groffen J, Heisterkamp N (1987) The BCR\/ABL hybrid gene. Baillieres Clin Haematol 1:983\u2013999","journal-title":"Baillieres Clin Haematol"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/306239a0","volume":"306","author":"N Heisterkamp","year":"1983","unstructured":"Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306:239\u2013242","journal-title":"Nature"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3324\/haematol.2010.035006","volume":"97","author":"H Herrmann","year":"2012","unstructured":"Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, J\u00e4ger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P (2012) CD34(+)\/CD38(\u2212) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin. Haematologica 97:219\u2013226","journal-title":"Haematologica"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, R\u00fclicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P (2014) Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 123:3951\u20133962","journal-title":"Blood"},{"key":"10_CR31","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, M\u00fcller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, Investigators IRIS (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.molcel.2011.08.026","volume":"44","author":"E Hodges","year":"2011","unstructured":"Hodges E, Molaro A, Dos Santos CO, Thekkat P, Song Q, Uren PJ, Park J, Butler J, Rafii S, McCombie WR, Smith AD, Hannon GJ (2011) Directional DNA methylation changes and complex intermediate states accompany lineage specificity in the adult hematopoietic compartment. Mol Cell 44:17\u201328","journal-title":"Mol Cell"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","volume":"94","author":"T Holyoake","year":"1999","unstructured":"Holyoake T, Jiang X, Eaves C, Eaves A (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94:2056\u20132064","journal-title":"Blood"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NCP, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337","journal-title":"Blood"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488\u20132498","journal-title":"N Engl J Med"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/ajh.24830","volume":"92","author":"A Janel","year":"2017","unstructured":"Janel A, Berger J, Bourgne C, Lemal R, Boiret-Dupr\u00e9 N, Dubois-Galopin F, D\u00e9chelotte P, Bothorel C, Hermet E, Chabi S, Bay J-O, Lambert C, Pereira B, Pflumio F, Haddad R, Berger MG (2017) Bone marrow hematons: an access point to the human hematopoietic niche. Am J Hematol 92:1020\u20131031","journal-title":"Am J Hematol"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M J\u00e4r\u00e5s","year":"2010","unstructured":"J\u00e4r\u00e5s M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, Lassen C, Olofsson T, Bjerrum OW, Richter J, Fioretos T (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci U S A 107:16280\u201316285","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109:4016\u20134019","journal-title":"Blood"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O\u2019Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E, International STI571 CML Study Group (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645\u2013652","journal-title":"N Engl J Med"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/JCO.1985.3.2.192","volume":"3","author":"HM Kantarjian","year":"1985","unstructured":"Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, Freireich EJ (1985) Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol Off J Am Soc Clin Oncol 3:192\u2013200","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","volume":"87","author":"MA Kelliher","year":"1990","unstructured":"Kelliher MA, McLaughlin J, Witte ON, Rosenberg N (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL. Proc Natl Acad Sci U S A 87:6649\u20136653","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.leukres.2017.06.009","volume":"59","author":"T Kim","year":"2017","unstructured":"Kim T, Tyndel MS, Zhang Z, Ahn J, Choi S, Szardenings M, Lipton JH, Kim H-J, Kim Dong Hwan D (2017) Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. Leuk Res 59:142\u2013148","journal-title":"Leuk Res"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","volume":"51","author":"S Koschmieder","year":"2018","unstructured":"Koschmieder S, Vetrie D (2018) Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options. Semin Cancer Biol 51:180\u2013197","journal-title":"Semin Cancer Biol"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/leu.2015.135","volume":"30","author":"N Landberg","year":"2016","unstructured":"Landberg N, Hansen N, Askmyr M, \u00c5gerstam H, Lassen C, Rissler M, Hjorth-Hansen H, Mustjoki S, J\u00e4r\u00e5s M, Richter J, Fioretos T (2016) IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome. Leukemia 30:253\u2013257","journal-title":"Leukemia"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcancer.2017.09.008","volume":"51","author":"J Langstein","year":"2018","unstructured":"Langstein J, Milsom MD, Lipka DB (2018) Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis. Semin Cancer Biol 51:89\u2013100","journal-title":"Semin Cancer Biol"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645\u2013648","journal-title":"Nature"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.4161\/15384101.2014.973334","volume":"13","author":"DB Lipka","year":"2014","unstructured":"Lipka DB, Wang Q, Cabezas-Wallscheid N, Klimmeck D, Weichenhan D, Herrmann C, Lier A, Brocks D, von Paleske L, Renders S, W\u00fcnsche P, Zeisberger P, Gu L, Haas S, Essers MA, Brors B, Eils R, Trumpp A, Milsom MD, Plass C (2014) Identification of DNA methylation changes at cis-regulatory elements during early steps of HSC differentiation using tagmentation-based whole genome bisulfite sequencing. Cell Cycle 13:3476\u20133487","journal-title":"Cell Cycle"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1182\/blood.V88.5.1796.1796","volume":"88","author":"V Maguer-Satta","year":"1996","unstructured":"Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ (1996) BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia. Blood 88:1796\u20131804","journal-title":"Blood"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"10_CR50","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/1878-0261.12191","volume":"12","author":"S Maupetit-Mehouas","year":"2018","unstructured":"Maupetit-Mehouas S, Court F, Bourgne C, Guerci-Bresler A, Cony-Makhoul P, Johnson H, Etienne G, Rousselot P, Guyotat D, Janel A, Hermet E, Saugues S, Berger J, Arnaud P, Berger MG (2018) DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15\u2212 cells in early chronic-phase chronic myeloid leukemia. Mol Oncol 12:814\u2013829","journal-title":"Mol Oncol"},{"key":"10_CR51","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/leu.2013.19","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markev\u00e4rn B, Olofsson T, Olsson-Str\u00f6mberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H, Nordic CML Study Group (NCMLSG) (2013) Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 27:1520\u20131526","journal-title":"Leukemia"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.exphem.2018.05.003","volume":"64","author":"FE Nicolini","year":"2018","unstructured":"Nicolini FE, Alcazer V, Cony-Makhoul P, Heiblig M, Morisset S, Fossard G, Bidet A, Schmitt A, Sobh M, Hayette S, Mahon F-X, Dulucq S, Etienne G (2018) Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Exp Hematol 64:97\u2013105.e4","journal-title":"Exp Hematol"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(02)00623-2","volume":"108","author":"H Pluk","year":"2002","unstructured":"Pluk H, Dorey K, Superti-Furga G (2002) Autoinhibition of c-Abl. Cell 108:247\u2013259","journal-title":"Cell"},{"key":"10_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0065-230X(08)60796-4","volume":"49","author":"WH Raskind","year":"1987","unstructured":"Raskind WH, Fialkow PJ (1987) The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 49:127\u2013167","journal-title":"Adv Cancer Res"},{"key":"10_CR55","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522","journal-title":"Blood"},{"key":"10_CR56","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290\u2013293","journal-title":"Nature"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O\u2019Brien S, So C, Massimini G, Guilhot F (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108:1478\u20131484","journal-title":"Blood"},{"key":"10_CR58","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Str\u00f6mberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machov\u00e1 Pol\u00e1kov\u00e1 K, M\u00fcller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann W-K, Hochhaus A, Pfirrmann M, Mahon F-X, investigators EURO-SKI (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757","journal-title":"Lancet Oncol"},{"key":"10_CR59","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"key":"10_CR60","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-97746-1_6","volume":"1100","author":"M Shah","year":"2018","unstructured":"Shah M, Bhatia R (2018) Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment. Adv Exp Med Biol 1100:97\u2013110","journal-title":"Adv Exp Med Biol"},{"key":"10_CR61","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","volume":"86","author":"T Skorski","year":"1995","unstructured":"Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86:726\u2013736","journal-title":"Blood"},{"key":"10_CR62","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","volume":"12","author":"KM Smith","year":"2003","unstructured":"Smith KM, Yacobi R, Van Etten RA (2003) Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 12:27\u201337","journal-title":"Mol Cell"},{"key":"10_CR63","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 12:7374\u20137379","journal-title":"Clin Cancer Res"},{"key":"10_CR64","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G (2013) Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 122:1634\u20131648","journal-title":"Blood"},{"key":"10_CR65","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1182\/blood.V74.5.1563.1563","volume":"74","author":"HJ Sutherland","year":"1989","unstructured":"Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM (1989) Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74:1563\u20131570","journal-title":"Blood"},{"key":"10_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y, Investigators TARGET (2011) Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35:585\u2013590","journal-title":"Leuk Res"},{"key":"10_CR67","doi-asserted-by":"publisher","first-page":"e559","DOI":"10.1038\/bcj.2017.36","volume":"7","author":"E Togasaki","year":"2017","unstructured":"Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T (2017) Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia. Blood Cancer J 7:e559","journal-title":"Blood Cancer J"},{"key":"10_CR68","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0140-6736(63)91620-9","volume":"1","author":"IM Tough","year":"1963","unstructured":"Tough IM, Jacobs PA, Court Brown WM, Baikie AG, Williamson ER (1963) Cytogenetic studies on bone-marrow in chronic myeloid leukaemia. Lancet Lond Engl 1:844\u2013846","journal-title":"Lancet Lond Engl"},{"key":"10_CR69","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1182\/blood.V80.10.2522.2522","volume":"80","author":"C Udomsakdi","year":"1992","unstructured":"Udomsakdi C, Eaves CJ, Lansdorp PM, Eaves AC (1992) Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 80:2522\u20132530","journal-title":"Blood"},{"key":"10_CR70","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","volume":"129","author":"R Warfvinge","year":"2017","unstructured":"Warfvinge R, Geironson L, Sommarin MNE, Lang S, Karlsson C, Roschupkina T, Stenke L, Stentoft J, Olsson-Str\u00f6mberg U, Hjorth-Hansen H, Mustjoki S, Soneji S, Richter J, Karlsson G (2017) Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood 129:2384\u20132394","journal-title":"Blood"},{"key":"10_CR71","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1182\/blood.V22.6.664.664","volume":"22","author":"J Whang","year":"1963","unstructured":"Whang J, Frei E, Tjio JH, Carbone PP, Brecher G (1963) The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood 22:664\u2013673","journal-title":"Blood"},{"key":"10_CR72","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC, Walter MJ, Mardis ER, Dipersio JF, Chen F, Wilson RK, Ley TJ, Ding L (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472\u20131478","journal-title":"Nat Med"},{"key":"10_CR73","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1128\/MCB.21.3.840-853.2001","volume":"21","author":"X Zhang","year":"2001","unstructured":"Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R (2001) The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol Cell Biol 21:840\u2013853","journal-title":"Mol Cell Biol"},{"key":"10_CR74","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood.V97.8.2406","volume":"97","author":"RC Zhao","year":"2001","unstructured":"Zhao RC, Jiang Y, Verfaillie CM (2001) A model of human p210(bcr\/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR\/ABL-containing retroviral vector. Blood 97:2406\u20132412","journal-title":"Blood"},{"key":"10_CR75","first-page":"117","volume":"9","author":"X Zhao","year":"2002","unstructured":"Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS (2002) Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 9:117\u2013120","journal-title":"Nat Struct Biol"}],"container-title":["Advances in Experimental Medicine and Biology","Stem Cells Heterogeneity in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-14366-4_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T05:04:36Z","timestamp":1649826276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-14366-4_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030143657","9783030143664"],"references-count":75,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-14366-4_10","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"28 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}